Rilzabrutinib dose 1

Phase 2

Sanofi

Rilzabrutinib dose 1 is one of 14 therapeutic programs targeting Graves disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Graves DiseaseRecruiting

Graves DiseasePhase 2

Recruiting

Competition

Competitive Landscape

19 competitors in Graves Disease

#DrugCompanyPhaseTrials

Tapazole

VViking Therapeutics, Inc.

Approved

6 2

Decadron

AAspen Global Incorporated

Approved

1 3

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—4

Synthroid

IInstitut Jerome Lejeune

Approved

—5

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Efgartigimod PH20 SC

2 7

Felzartamab

Biogen

Phase 2

1 8

IMVT-1402

IImmunovant Sciences GmbH

Phase 2

3 9

BHV-1300

BBiohaven Therapeutics Ltd.

Phase 3

2 10

Rilzabrutinib Dose 2

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Graves Disease

NCT06984627

Clinical

Trials by Indication[1]

Graves disease1 trial

An Open-label Phase 2 Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease

Recruiting· Sanofi logo

Sanofi·Phase 2·NCT06984627·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Rilzabrutinib dose 1. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Rilzabrutinib dose 1. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: Sanofi

Rilzabrutinib dose 1

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2026

Trials by Indication[1]

Graves disease1 trial

References

Drug Info

Quick Facts

Related News